シンポジウム18：GBS・CIDP 2024UPDATE
GBS・CIDPの疫学UPDATE
キーワード:
Guillain–Barré syndrome,
chronic inflammatory demyelinating polyradicuroneuropathy,
COVID–19,
epidemiology
2025 年 42 巻 4 号 p. 550-553
詳細
2025 年 42 巻 4 号 p. 550-553
Guillain–Barre syndrome (GBS) and chronic inflammatory demyelinating polyradicuroneuropathy (CIDP) are major immune–mediated neuropathies. Since the pandemic of coronavirus disease 2019 (COVID–19) in 2020, verious neurolgical complications caused by COVID–19, especially GBS, have been increasingly reported. The epidemiology of GBS has changed with the emergence of COVID–19 and lifestyle changes due to the pandemic. As for CIDP, in 2021, the second revision of the international guideline resulted in a new clinical classification of CIDP, and the improtance of clinical classification has been highlited. From these backgrounds, natonwide epidemiological surveys of GBS and CIDP were conducted in Japan. This artitle describes recent epidemiology of GBS and CIDP, focusing on the results of nationwide surveys.
